Peter Roald Bergethon BA, MD

Peter R. Bergethon, M.D. is vice president and Head of Quantitative Medicine and Clinical Technologies (QMCT) at Biogen. He leads the identification of technologies and methodologies that transform drug development. QMCT creates value by leading the transition of clinical practice in Biogen’s core and emerging growth areas from a qualitative to a quantitative discipline, and connecting the clinical with the research enterprise, to advance therapeutics and personalized medicine.

Peter came to Biogen in 2017 from Pfizer Worldwide Research and Development where he was vice president and head of the Pfizer Innovation Research Lab within the Early Clinical Development group.

At Pfizer, Peter led both the Quantitative Medicine group and the Innovation Research Labs where he pioneered mobile and digital clinical assessment technology, human neuro phenotyping, and multi-modal data analytics to accelerate clinical development in neuroscience, immunology, rare diseases, and cardiometabolic disease.

He is an accomplished clinical neurologist and neuroscientist who, prior to joining Pfizer, was a professor at Boston University and Tufts University in the Departments of Biochemistry, Neurology, Neurobiology & Anatomy, and Biomedical Engineering.